Valuation: Aprogen Biologics Inc.

Capitalization 131B 90.51M 86.67M 81.87M 72.19M 129M 7.85B 144M 975M 362M 3.27B 339M 332M 13.84B P/E ratio 2022
26.5x
P/E ratio 2023 -1.55x
Enterprise value 302B 209M 200M 189M 167M 297M 18.11B 331M 2.25B 834M 7.54B 783M 767M 31.94B EV / Sales 2022
3.62x
EV / Sales 2023 4.14x
Free-Float
23.46%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 13 CI
Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 24-08-14 CI
Aprogen Biologics Inc. announced that it has received KRW 70.000000384 billion in funding from Aprogen Medicines Inc. 24-07-31 CI
An undisclosed buyer agreed to acquire 6.87% stake in Aprogen Biologics Inc. from Aprogen Medicines Inc. for KRW 43.9 billion. 24-07-22 CI
Aprogen Biologics Inc. announced that it expects to receive KRW 70.000000384 billion in funding from Aprogen Medicines Inc. 24-07-03 CI
Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 24-05-14 CI
Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 24-03-13 CI
Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 23-11-13 CI
Aprogen Biologics Inc.(KOSE:A003060) dropped from S&P Global BMI Index 23-09-18 CI
Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 23-08-14 CI
Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 23-05-12 CI
Aprogen Biologics Inc. announced that it has received KRW 20 billion in funding from Aprogen, Inc. 23-04-23 CI
Aprogen Biologics Inc. announced that it expects to receive KRW 20 billion in funding from Aprogen, Inc. 23-04-20 CI
More news
1 day+8.96%
Current month-3.95%
1 month+11.79%
3 months-6.05%
6 months-28.64%
Current year+10.27%
More quotes
1 week
657.00
Extreme 657
759.00
1 month
600.00
Extreme 600
879.00
Current year
600.00
Extreme 600
879.00
1 year
600.00
Extreme 600
2 350.00
3 years
600.00
Extreme 600
10 150.00
5 years
600.00
Extreme 600
28 500.00
10 years
600.00
Extreme 600
100 400.00
More quotes
Director TitleAgeSince
Chief Executive Officer 62 -
Chief Executive Officer 68 2012-03-31
Sales & Marketing 61 -
Manager TitleAgeSince
Director/Board Member 68 2012-03-31
Director/Board Member 61 -
Director/Board Member 64 2020-03-22
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+8.96%0.00%-61.58%-90.63% 99.81M
-0.13%+0.17%+17.35%+269.84% 785B
+1.28%+2.44%+0.50%-6.24% 379B
-0.19%-10.26%-33.36%+75.52% 352B
+0.23%+0.25%+11.63%+36.22% 342B
-0.69%+2.32%+30.15%-13.59% 264B
-0.94%+2.00%+21.68%+41.18% 233B
-1.46%-4.12%-32.70%+10.15% 214B
-1.11%-0.10%+10.17%+22.15% 214B
+0.65%-0.27%+2.23%+30.14% 160B
Average +0.72%-0.16%-3.39%+37.47% 294.11B
Weighted average by Cap. -0.17%-0.06%+4.97%+90.48%
See all sector performances

Financials

2022 2023
Net sales 65.19B 45.11M 43.2M 40.8M 35.98M 64.13M 3.91B 71.6M 486M 180M 1.63B 169M 166M 6.9B 87.36B 60.46M 57.89M 54.68M 48.22M 85.95M 5.24B 95.95M 651M 242M 2.18B 227M 222M 9.25B
Net income 7.84B 5.42M 5.19M 4.91M 4.33M 7.71M 470M 8.61M 58.41M 21.67M 196M 20.33M 19.92M 829M -118B -81.85M -78.37M -74.03M -65.28M -116M -7.1B -130M -882M -327M -2.95B -307M -301M -12.52B
Net Debt 35.66B 24.68M 23.63M 22.32M 19.68M 35.09M 2.14B 39.17M 266M 98.62M 891M 92.5M 90.66M 3.77B 171B 118M 113M 107M 94.35M 168M 10.26B 188M 1.27B 473M 4.27B 443M 435M 18.09B
More financial data * Estimated data
Logo Aprogen Biologics Inc.
Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).
Employees
377
More about the company
Date Price Change Volume
25-02-13 730.00 +8.96% 1,840,303
25-02-12 670.00 -3.04% 463,169
25-02-11 691.00 +1.62% 423,906
25-02-10 680.00 -1.16% 572,323
25-02-07 688.00 -5.75% 1,238,544

End-of-day quote Korea S.E., February 12, 2025

More quotes
  1. Stock Market
  2. Equities
  3. A003060 Stock